EGFR and non-small cell lung carcinoma: Additionally, the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for NSCLC [16] now recommend Osimertinib as the first-line treatment option for patients with EGFR activating mutation-positive NSCLC.